USD 6.39 Billion
Report ID:
SQMIG35H2218 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
73 |
Figures:
75
Gene Therapy Market size was valued at USD 6.39 Billion in 2021 and is poised to grow from USD 7.60 Billion in 2022 to USD 38.34 Billion by 2030, at a CAGR of 19% during the forecast period (2023-2030).
The global gene therapy market is a rapidly growing market that is poised for significant growth in the coming years. The purpose of the gene therapy market is to provide a cure for genetic disorders that are currently untreatable. Gene therapy market is focused on developing new and innovative therapies that can address the root cause of these diseases.
The key driving factors for the gene therapy market is the increasing prevalence of genetic disorders. The prevalence of genetic disorders is increasing globally, which is driving the demand for gene therapy. The main restraints for the gene therapy market are the high cost of these therapies. Gene therapies are complex and expensive to develop, which results in high costs for patients. The delivery mechanism is critical for the success of gene therapies, as it needs to deliver the healthy gene to the targeted cells in the body. Additionally, the immune system can recognize the gene therapy as a foreign invader, which can lead to an immune response that reduces the effectiveness of the therapy. The gene therapy market presents a significant opportunity for pharmaceutical companies to develop new and innovative therapies.
US Gene Therapy Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 6.39 Billion
Largest Segment
Retrovirus & gamma Retrovirus
Fastest Growth
Retrovirus & gamma Retrovirus
Growth Rate
19% CAGR
To get more reports on the above market click here to Buy The Report
The global gene therapy market is segmented on the basis of vector, indication, and region. Based on vectors, the market is segmented into lentivirus, AAV, retrovirus & gamma retrovirus, modified herpes simplex virus, adenovirus, non-viral plasmid vector, and others. In terms of indication, the market is segmented into acute lymphoblastic leukemia (ALL), inherited retinal disease, large B-cell lymphoma, melanoma (lesions), beta-thalassemia major/SCD, head & neck squamous cell carcinoma, peripheral arterial disease, spinal muscular atrophy (SMA), and others. Regionwise, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Gene Therapy Market Analysis by Vector
In 2022, retroviruses segment accounted for over 20% of the revenue share in the global gene therapy market due to their ease of isolation and incorporation of DNA into the virus, allowing the conversion of single-stranded RNA to double-stranded DNA for integration into host cell chromosomes. Ongoing clinical trials are predominantly using retroviruses, and the approval of Yes carta in 2017 has led to a significant revenue growth in this segment. Meanwhile, Adeno-Associated Viral (AAV) vectors are expected to show substantial market share growth in the future. AAVs have become highly sought after and their clinical trial applications are increasing annually due to their ability to deliver genes to the region of interest with the highest efficiency. The rise of AAV usage can be attributed to the success of orthopedic and ocular gene therapy treatments, which have shown increased efficacy. Therefore, AAV is expected to witness a significant adoption rate boost in various therapeutic fields during the forecast period.
Gene Therapy Market Analysis by Indication
As of 2022, spinal muscular atrophy (SMA) holds the largest market share of 43.44% in terms of revenue. Although SMA is rare, it is a fatal inherited disease that commonly affects infants. Zolgensma (AVXS-101), developed to treat SMA, has been proven to be effective and has altered the phenotypic of the illness. In May 2019, the FDA approved Novartis' Zolgensma, making it the only gene therapy for SMA to be approved. This approval demonstrates the growing use of gene therapies to treat serious hereditary illnesses like SMA. The inherited retinal disease segment is expected to have a significant compound annual growth rate (CAGR) during the forecast period. R&D activities for developing gene therapies to treat ocular diseases, including inherited retinal disease, have driven this segment. Spark Therapeutics commercializes Luxturna in the U.S. and Novartis outside the U.S. as a treatment for a form of inherited retinal disease. Luxturna is the first gene therapy that can be directly administered to target a genetic disease caused by mutations in a single genetic factor.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America emerged as the dominant region in the gene therapy market, contributing to over 65.0% of the overall revenue. It is projected to remain the largest routine manufacturer of gene therapy drugs during the forecast period, with increasing investments in R&D by companies of all sizes. The market is being driven by rising government investments and the growing prevalence of targeted diseases in the region, such as spinal muscular atrophy, affecting 10,000 to 25,000 individuals in the U.S. alone, according to the Spinal Muscular Atrophy Foundation.
Asia Pacific is expected to be the fastest-growing regional segment from 2023 to 2030, owing to its large population with unmet medical needs and the growing demand for innovative technologies to treat rare but increasingly prevalent diseases. The commercial application of genetic therapies is likely to witness significant growth in this region due to the availability of resources, the presence of major companies, and government investments.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Gene Therapy Market Drivers
Increasing Prevalence of Genetic Disorders
Rising Demand for Personalized Medicine
Gene Therapy Market Restraints
High Costs
Regulatory Hurdles
Request Free Customization of this report to help us to meet your business objectives.
The global gene therapy market is highly competitive with a large number of players operating in the industry. The key players in the market are focusing on the development of new and advanced therapies to enhance their market presence. The gene therapy market is highly competitive, with a number of players focusing on the development of novel therapies for the treatment of a range of diseases. The market is expected to continue to grow in the coming years, driven by increasing investment in R&D and growing demand for new and advanced therapies for the treatment of rare and life-threatening diseases.
Gene Therapy Market Top Player’s Company Profiles
Gene Therapy Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global gene therapy market analysis, the increasing investments in R&D activities, the growing prevalence of targeted diseases, and rising demand for novel technologies in the treatment of rare but increasingly prevalent diseases are the key growth drivers. The market is also driven by the increasing number of clinical trials and approvals by regulatory bodies for gene therapy products. The competitive landscape of the gene therapy market is highly fragmented, with the presence of several small and large players. Some of the key players in the market include Novartis International AG (Switzerland), Pfizer Inc. (US), Spark Therapeutics Inc. (US), bluebird bio, Inc. (US), and uniQure N.V. (Netherlands). These players are focusing on strategies such as collaborations, partnerships, and acquisitions to expand their market presence and improve their product portfolios. The global gene therapy market is expected to witness significant growth in the coming years due to the increasing demand for targeted and personalized therapies, rising investments in R&D activities, and the growing prevalence of targeted diseases.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 6.39 Billion |
Market size value in 2031 | USD 38.34 Billion |
Growth Rate | 19% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Gene Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Gene Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Gene Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Gene Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2218